Research location
Rozzano
Italy
Advertisement
Research activity in Rozzano
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 189 trials and 190 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rozzano
189 linked trials · page 2 of 4Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaNCT07858123 · 2026-11-16 · 1 site observation
NOT_YET_RECRUITING
Nipocalimab in Moderate to Severe Sjogren's DiseaseNCT06741969 · 2024-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · 2024-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754 · 2024-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)NCT06162572 · 2024-08-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302 · 2024-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPNCT06188702 · 2024-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873 · 2024-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyNCT06041386 · 2024-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerNCT06239467 · 2024-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)NCT06215911 · 2024-02-13 · 1 site observation
COMPLETED
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationNCT06039384 · 2023-12-28 · 1 site observation
TERMINATED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)NCT05882734 · 2023-09-13 · 1 site observation
COMPLETED
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.NCT05803395 · 2023-09-12 · 1 site observation
UNKNOWN
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyNCT05840211 · 2023-05-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO StudyNCT06464341 · 2023-05-04 · 1 site observation
COMPLETED
A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in ItalyNCT05759273 · 2023-04-24 · 1 site observation
COMPLETED
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDNCT05819359 · 2023-03-31 · 1 site observation
ACTIVE_NOT_RECRUITING
ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerNCT05650879 · 2023-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Core Stability as a Prognostic Factor of Urinary Incontinence in Patients Undergoing Robot-assisted Laparoscopic ProstatectomyNCT05893394 · 2023-03-01 · 1 site observation
UNKNOWN
Setting a PERSONalized Outcome in ASthma: the PERSONAS Study. A Patient Driven Outcome (PDO) StudyNCT06320119 · 2023-01-01 · 2 site observations
UNKNOWN
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
First in Human Study of AZD9592 in Solid TumorsNCT05647122 · 2022-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyNCT05450692 · 2022-09-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerNCT05403385 · 2022-08-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.NCT05408039 · 2022-07-14 · 1 site observation
COMPLETED
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · 2022-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922 · 2022-07-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer TreatmentNCT05377684 · 2022-06-09 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974 · 2022-05-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)NCT05374512 · 2022-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationNCT05253807 · 2022-04-29 · 1 site observation
COMPLETED
PSMA PET/CT vs. mpMRI in Patients With a High Suspicion of Prostate Cancer: a Head to Head, Parallel, Prospective TrialNCT05297162 · 2022-04-01 · 1 site observation
UNKNOWN
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · 2022-02-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerNCT05113251 · 2021-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target TherapyNCT05754502 · 2021-07-27 · 1 site observation
UNKNOWN
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)NCT04964934 · 2021-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284 · 2021-06-07 · 1 site observation
COMPLETED
Alectinib in Neo-adjuvant Treatment of Stage III NSCLCNCT05015010 · 2021-05-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · 2021-04-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)NCT04644237 · 2021-03-19 · 1 site observation
COMPLETED
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerNCT04702880 · 2021-03-17 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.